Drug intelligence / Profile preview

Crocal Plus

Development stage: Unknown
Lead developer: Croise Pharma
Modality: Small Molecules
Administration: Oral

Overview

Crocal Plus is an oral nutritional supplement developed by Croise Pharma. It is formulated as a tablet containing a combination of calcium citrate (1000 mg), magnesium (100 mg), zinc (4 mg), and calcitriol (0.25 mcg). Crocal Plus is primarily indicated for the treatment and prevention of nutritional deficiencies and bone disorders such as osteoporosis, osteomalacia, rickets, hypoparathyroidism, and latent tetany. Calcitriol, the active form of vitamin D3, facilitates intestinal absorption of calcium and phosphorus, while calcium citrate provides the essential mineral for bone mineralization. Magnesium and zinc support bone formation, healing, and overall physiological maintenance.

Brand names: Crocal Plus
Other names: CROCAL Plus TabCrocal Plus Tablet

Targets

CaSR (Extracellular calcium-sensing receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Crocal Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crocal Plus.